AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dihydralazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antihypertensives, hydrazinephthalazine derivatives | 884 | 484-23-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 75 | mg | O |
| 25 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | AAK1,ACVR1B,ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK5,CDK7,CDK9,CHEK1,CLK4,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FLT3,GRK1,GRK2,GRK3,GSK3B,IKBKB,IRAK1,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PIM1,PIM2,PLK1,PRKAA1,PRKAA2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TNIK,TTK,ULK1,ULK2 | 86 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AURKB,AXL,BRAF,CAMK2D,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,MAP2K3,MAP2K6,MAP3K10,MAP3K21,MAPK7,MARK4,SGK1,SIK2,STK33,TEK,TTK,ULK1 | 23 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Patent ductus arteriosus | 104.23 | 56.37 | 18 | 393 | 4551 | 90623485 |
| Language disorder | 64.16 | 56.37 | 11 | 400 | 2641 | 90625395 |
| Premature baby | 63.57 | 56.37 | 16 | 395 | 25061 | 90602975 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Shone complex | 106.68 | 62.84 | 13 | 648 | 72 | 42620602 |
| Ventricular septal defect | 93.99 | 62.84 | 20 | 641 | 4379 | 42616295 |
| Patent ductus arteriosus | 86.90 | 62.84 | 18 | 643 | 3458 | 42617216 |
| Atrial septal defect | 82.28 | 62.84 | 20 | 641 | 7899 | 42612775 |
| Product prescribing error | 70.70 | 62.84 | 23 | 638 | 26089 | 42594585 |
| Aorta hypoplasia | 67.80 | 62.84 | 9 | 652 | 106 | 42620568 |
| Supravalvular aortic stenosis | 65.98 | 62.84 | 8 | 653 | 42 | 42620632 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Product prescribing error | 97.23 | 48.08 | 29 | 800 | 51302 | 110537168 |
| Acute graft versus host disease in skin | 68.91 | 48.08 | 16 | 813 | 10724 | 110577746 |
| Product monitoring error | 55.67 | 48.08 | 13 | 816 | 8914 | 110579556 |
| Language disorder | 54.51 | 48.08 | 11 | 818 | 3827 | 110584643 |
| Mitral valve hypoplasia | 54.08 | 48.08 | 6 | 823 | 30 | 110588440 |
| Shone complex | 54.08 | 48.08 | 6 | 823 | 30 | 110588440 |
| Congenital aortic valve stenosis | 53.91 | 48.08 | 6 | 823 | 31 | 110588439 |
| Aorta hypoplasia | 53.45 | 48.08 | 6 | 823 | 34 | 110588436 |
| Congenital heart valve disorder | 52.61 | 48.08 | 6 | 823 | 40 | 110588430 |
| Coarctation of the aorta | 49.68 | 48.08 | 6 | 823 | 69 | 110588401 |
| Labelled drug-drug interaction medication error | 48.71 | 48.08 | 15 | 814 | 29287 | 110559183 |
| Gallbladder enlargement | 48.37 | 48.08 | 9 | 820 | 2053 | 110586417 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C02DB01 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON Hydrazinophthalazine derivatives |
| ATC | C02LG01 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Hydrazinophthalazine derivatives and diuretics |
| ATC | C02LG51 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Hydrazinophthalazine derivatives and diuretics |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D014665 | Vasodilator Agents |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
Related Drugs by ATC class:
C02DB Hydrazinophthalazine derivatives 3 drugs
C02LG Hydrazinophthalazine derivatives and diuretics 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.51 | Basic |
| pKa2 | 9.9 | Basic |
| pKa3 | 4.95 | Basic |
| pKa4 | 4.35 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| N0000167108 | NUI |
| D07170 | KEGG_DRUG |
| 235959 | RXNORM |
| C0012271 | UMLSCUI |
| CHEBI:134841 | CHEBI |
| CHEMBL35505 | ChEMBL_ID |
| DB12945 | DRUGBANK_ID |
| D004078 | MESH_DESCRIPTOR_UI |
| 10230 | PUBCHEM_CID |
| 245 | INN_ID |
| PCU411F5L6 | UNII |
| 004347 | NDDF |
| 004348 | NDDF |
| 703113001 | SNOMEDCT_US |
| 703114007 | SNOMEDCT_US |
| D006830 | MESH_DESCRIPTOR_UI |
| CHEMBL2106266 | ChEMBL_ID |
| 7327-87-9 | SECONDARY_CAS_RN |
Pharmaceutical products:
None